Comparative Pharmacology
Head-to-head clinical analysis: AMOXICILLIN AND CLAVULANATE POTASSIUM versus AUGMENTIN XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMOXICILLIN AND CLAVULANATE POTASSIUM versus AUGMENTIN XR.
AMOXICILLIN AND CLAVULANATE POTASSIUM vs AUGMENTIN XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Clavulanate potassium is a beta-lactamase inhibitor that irreversibly inactivates beta-lactamase enzymes, preventing degradation of amoxicillin.
Amoxicillin is a beta-lactam antibacterial that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Clavulanate is a beta-lactamase inhibitor that irreversibly binds to and inactivates beta-lactamase enzymes, protecting amoxicillin from degradation.
500 mg amoxicillin/125 mg clavulanate orally every 8 hours or 875 mg amoxicillin/125 mg clavulanate orally every 12 hours. For severe infections: 875 mg amoxicillin/125 mg clavulanate orally every 8 hours or 1000 mg amoxicillin/62.5 mg clavulanate extended-release orally every 12 hours.
Adults and adolescents ≥16 years: 2 tablets (amoxicillin 1000 mg/clavulanate 62.5 mg per tablet) orally every 12 hours for 10 days.
None Documented
None Documented
Amoxicillin: ~1-1.5 hours; Clavulanate: ~1 hour. Prolonged in renal impairment.
Amoxicillin: ~1.0-1.3 hours; clavulanate: ~0.9-1.2 hours; prolonged in renal impairment (creatinine clearance <30 mL/min: amoxicillin half-life up to 7-14 hours).
Renal: ~50-70% amoxicillin unchanged; ~25-40% clavulanate as metabolites. Fecal: minimal. Biliary: minor.
Amoxicillin: ~50-70% excreted unchanged in urine via glomerular filtration and tubular secretion; clavulanate: ~25-40% excreted unchanged in urine; both undergo minor biliary/fecal elimination (<10%).
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic